Peering Into Recursion Pharmaceuticals's Recent Short Interest
Portfolio Pulse from Benzinga Insights
Recursion Pharmaceuticals (NYSE:RXRX) has seen a 3.06% increase in short interest since its last report, with 37.02 million shares sold short, representing 26.94% of its float. The short interest is higher than the peer group average of 14.47%. High short interest can indicate bearish market sentiment but can also be bullish if it leads to a short squeeze.
January 01, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Recursion Pharmaceuticals has a significant increase in short interest, which may suggest bearish sentiment or potential for a short squeeze.
The increase in short interest for Recursion Pharmaceuticals indicates that investors may be expecting the stock price to decline. However, high short interest can also lead to a short squeeze if the stock price starts to rise and short sellers rush to cover their positions. The impact on the stock price in the short term is uncertain, hence a neutral score is given.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100